ENLIVEN THERAPEUTICS, INC. (ELVN) EBITDA
- 2026-06-30: Basis Reported; EBITDA -$37.2M; Operating income (m); Depreciation and amortization (m).
- 2026-03-31: Basis Reported; EBITDA -$27.81M; Operating income (m); Depreciation and amortization (m).
- 2025-12-31: Basis Reported; EBITDA -$34.2M; Operating income (m); Depreciation and amortization (m).
- 2025-09-30: Basis Reported; EBITDA -$25.03M; Operating income (m); Depreciation and amortization (m).
Complete source-backed ebitda history.
- Available history
- 2022-03-31 to 2026-06-30
- Data captured
Historical EBITDA
EBITDA 3 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|
| 2026-06-30 | Reported | -$37.2M | (m) | (m) | (m) | (m) | (m) | -$18.53M* | (m) | $29.00M | (m) | (m) |
|---|
| 2026-03-31 | Reported | -$27.81M | (m) | (m) | (m) | (m) | (m) | -$19.29M | (m) | $20.69M | (m) | (m) |
|---|
| 2025-12-31 | Reported | -$34.2M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
|---|
| 2025-09-30 | Reported | -$25.03M | (m) | (m) | (m) | (m) | (m) | -$13.28M* | (m) | $18.23M | (m) | $0.00 |
|---|
| 2025-06-30 | Reported | -$28.5M | (m) | (m) | (m) | (m) | (m) | -$17.06M* | (m) | $21.49M | (m) | $0.00 |
|---|
| 2025-03-31 | Reported | -$31.62M | (m) | (m) | (m) | (m) | (m) | -$24.13M | (m) | $24.89M | (m) | (m) |
|---|
| 2024-12-31 | Reported | -$26.83M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
|---|
| 2024-09-30 | Reported | -$26.99M | (m) | (m) | (m) | (m) | (m) | -$12.19M* | (m) | $21.26M | (m) | $0.00 |
|---|
| 2024-06-30 | Reported | -$24.52M | (m) | (m) | (m) | (m) | (m) | -$20.43M* | (m) | $18.83M | (m) | $232.00K |
|---|
| 2024-03-31 | Reported | -$25.91M | (m) | (m) | (m) | (m) | (m) | -$23.36M | (m) | $19.97M | (m) | (m) |
|---|
| 2023-12-31 | Reported | -$22.65M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
|---|
| 2023-09-30 | Reported | -$24.17M | (m) | (m) | (m) | (m) | (m) | -$15.89M* | (m) | $19.61M | (m) | $0.00 |
|---|
| 2023-06-30 | Reported | -$20.06M | (m) | (m) | (m) | (m) | (m) | -$12.05M* | (m) | $15.18M | (m) | (m) |
|---|
| 2023-03-31 | Reported | -$16.35M | (m) | (m) | (m) | (m) | (m) | -$20.84M | (m) | $11.88M | (m) | (m) |
|---|
| 2022-12-31 | Reported | -$10.11M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
|---|
| 2022-09-30 | Reported | -$10.87M | (m) | (m) | (m) | (m) | (m) | -$6.45M* | (m) | $7.83M | (m) | (m) |
|---|
| 2022-06-30 | Reported | -$8.96M | (m) | (m) | (m) | (m) | (m) | -$7.12M* | (m) | $7.94M | (m) | (m) |
|---|
| 2022-03-31 | Reported | $30.32M | (m) | (m) | (m) | (m) | (m) | -$10.36M | (m) | $7.06M | (m) | (m) |
|---|
| 2021-09-30 | Reported | (m) | -$13.66M | (m) | (m) | (m) | (m) | -$10.90M* | (m) | $10.40M | (m) | (m) |
|---|
| 2021-06-30 | Reported | (m) | -$13.17M | (m) | (m) | (m) | (m) | -$10.37M* | (m) | $10.07M | (m) | (m) |
|---|
| 2021-03-31 | Reported | (m) | -$10.28M | (m) | (m) | (m) | (m) | -$13.02M | (m) | $7.12M | (m) | (m) |
|---|
| 2020-09-30 | Reported | (m) | -$12.49M | (m) | (m) | (m) | (m) | -$10.35M* | (m) | $9.53M | (m) | (m) |
|---|
| 2020-06-30 | Reported | (m) | -$10.30M | (m) | (m) | (m) | (m) | -$9.26M* | (m) | $7.87M | (m) | (m) |
|---|
| 2020-03-31 | Reported | (m) | -$7.35M | (m) | (m) | (m) | (m) | -$9.53M | (m) | $5.79M | (m) | (m) |
|---|
| 2019-09-30 | Reported | (m) | -$6.88M | (m) | (m) | (m) | (m) | -$6.28M* | (m) | $5.14M | (m) | (m) |
|---|
| 2019-06-30 | Reported | (m) | -$5.56M | (m) | (m) | (m) | (m) | -$5.15M* | (m) | $4.37M | (m) | (m) |
|---|
| 2019-03-31 | Reported | (m) | -$4.19M | (m) | (m) | (m) | (m) | -$2.41M | (m) | $3.56M | (m) | (m) |
|---|
EBITDA 12 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|
| 2025-12-31 | Reported | -$119.36M | (m) | (m) | (m) | (m) | (m) | -$70.30M | (m) | $85.86M | (m) | $0.00 |
|---|
| 2024-12-31 | Reported | -$104.25M | (m) | (m) | (m) | (m) | (m) | -$73.19M | (m) | $80.78M | (m) | $232.00K |
|---|
| 2023-12-31 | Reported | -$83.23M | (m) | (m) | (m) | (m) | (m) | -$61.27M | (m) | $64.57M | (m) | $0.00 |
|---|
| 2022-12-31 | Reported | -$38.59M | (m) | (m) | (m) | (m) | (m) | -$32.08M | (m) | $31.02M | (m) | $0.00 |
|---|
| 2021-12-31 | Reported | -$24.66M* | -$24.76M | $100.00K | (m) | (m) | (m) | -$19.13M | (m) | $20.47M | (m) | (m) |
|---|
| 2020-12-31 | Reported | (m) | -$41.70M | (m) | (m) | (m) | (m) | -$37.40M | (m) | $32.15M | (m) | (m) |
|---|
| 2019-12-31 | Reported | (m) | -$24.12M | (m) | (m) | (m) | (m) | -$21.88M | (m) | $19.01M | (m) | (m) |
|---|